F
Filipe Martins
Researcher at University Hospital of Lausanne
Publications - 12
Citations - 1267
Filipe Martins is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Immunotherapy & Acute leukemia. The author has an hindex of 6, co-authored 12 publications receiving 613 citations. Previous affiliations of Filipe Martins include University of Lausanne & École Polytechnique Fédérale de Lausanne.
Papers
More filters
Journal ArticleDOI
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Filipe Martins,Filipe Martins,Latifyan Sofiya,Gerasimos P. Sykiotis,Faiza Lamine,Michel H. Maillard,Montserrat Fraga,Keyvan Shabafrouz,Camillo Ribi,Anne Cairoli,Yan Guex-Crosier,Thierry Kuntzer,Olivier Michielin,Solange Peters,Georges Coukos,Georges Coukos,François Spertini,John A. Thompson,Michel Obeid,Michel Obeid +19 more
TL;DR: The epidemiology, treatment and management of the various immune-related adverse events that can occur in patients receiving immune-checkpoint inhibitors are described.
Journal ArticleDOI
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Filipe Martins,Filipe Martins,Gerasimos P. Sykiotis,Michel H. Maillard,Montserrat Fraga,Camillo Ribi,Thierry Kuntzer,Olivier Michielin,Solange Peters,Georges Coukos,Georges Coukos,François Spertini,John A. Thompson,John A. Thompson,Michel Obeid,Michel Obeid +15 more
TL;DR: A so-called shut-off strategy that aims at inhibiting key inflammatory components involved in the pathophysiological processes of immune-related adverse events, and limits potential adverse effects of drug immunosuppression on tumour response is proposed.
Journal ArticleDOI
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Filipe Martins,Filipe Martins,Luis Schiappacasse,Marc Levivier,Constantin Tuleasca,Constantin Tuleasca,Constantin Tuleasca,Michel A. Cuendet,Michel A. Cuendet,Michel A. Cuendet,Veronica Aedo-Lopez,Bianca Gautron Moura,Krisztian Homicsko,Adrienne Bettini,Gregoire Berthod,Camille L. Gerard,Alexandre Wicky,Jean Bourhis,Olivier Michielin +18 more
TL;DR: The concurrent administration of anti-PD-1+/−CTLA-4 mAbs with SRS was associated with improved survival in melanoma patients with newly diagnosed BM and the extension of systemic disease retains its prognostic value in patients treated with S RS.
Journal ArticleDOI
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Sophie Voruz,Filipe Martins,Anne Cairoli,Olaia Naveiras,Krisztian Homicsko,Edoardo Missiaglia,Laurence de Leval,Bettina Bisig,Olivier Michielin,Sabine Blum +9 more
TL;DR: The patient progressed under imatinib treatment, as already planned and mentioned in the paper, and started a 6th line of therapy with nivolumab in June 2017.
Journal ArticleDOI
Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.
TL;DR: A review of cHL immune escape mechanisms and an overview of new combinatory therapeutic perspectives where cHL immunotherapy may be considered, focusing on cHL biological sensitivity to PD-1 blockade.